A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
01 2019
Historique:
received: 09 04 2018
revised: 06 06 2018
accepted: 07 06 2018
entrez: 14 2 2019
pubmed: 14 2 2019
medline: 12 2 2020
Statut: ppublish

Résumé

The optimal preventive strategy for contrast induced acute kidney injury (CIAKI) in patients undergoing cardiac catheterization remains uncertain. We conducted Bayesian network meta-analysis (NMA) to compare different preventive strategies for CIAKI in these cohorts. Forty-nine randomized controlled trials were extracted using MEDLINE, EMBASE and CENTRAL data bases (inception-1st December 2017). We calculated median of the odds ratio (OR) with the corresponding 95% credible interval (CrI). The ranking probability of each treatment was based on SUCRA (surface under the cumulative ranking curve). In NMA of 28,063 patients [normal saline (NS: 9716 patients), sodium bicarbonate (NaHCO3: 4484 patients), statin (2542 patients), N-acetylcysteine (NAC: 3006 patients), NAC + NaHCO3 (774 patients), NS + NAC (3807 patients), NS + NaHCO3 (135 patients) and placebo (3599 patients)], statins reduced the relative risk of CIAKI compared with NS (OR: 0.50; 95% CrI, 0.25-0.99), and placebo (OR: 0.44; 95% CrI, 0.24-0.83). Subgroup analyses showed that in patients receiving low osmolar contrast, statins reduced the relative risk of CIAKI by 58% versus NS, and 51% versus placebo. There were no significant differences across all the treatments in terms of risk of hemodialysis or all-cause mortality. Statins had the highest probability for reducing the risk of CIAKI (SUCRA, 0.86), risk of hemodialysis (SUCRA, 0.88) and all-cause mortality (SUCRA, 0.81). Statins were the superior preventive strategy for reducing the risk of CIAKI compared with NS alone and placebo.

Sections du résumé

BACKGROUND
The optimal preventive strategy for contrast induced acute kidney injury (CIAKI) in patients undergoing cardiac catheterization remains uncertain.
OBJECTIVE
We conducted Bayesian network meta-analysis (NMA) to compare different preventive strategies for CIAKI in these cohorts.
METHODS
Forty-nine randomized controlled trials were extracted using MEDLINE, EMBASE and CENTRAL data bases (inception-1st December 2017). We calculated median of the odds ratio (OR) with the corresponding 95% credible interval (CrI). The ranking probability of each treatment was based on SUCRA (surface under the cumulative ranking curve).
RESULTS
In NMA of 28,063 patients [normal saline (NS: 9716 patients), sodium bicarbonate (NaHCO3: 4484 patients), statin (2542 patients), N-acetylcysteine (NAC: 3006 patients), NAC + NaHCO3 (774 patients), NS + NAC (3807 patients), NS + NaHCO3 (135 patients) and placebo (3599 patients)], statins reduced the relative risk of CIAKI compared with NS (OR: 0.50; 95% CrI, 0.25-0.99), and placebo (OR: 0.44; 95% CrI, 0.24-0.83). Subgroup analyses showed that in patients receiving low osmolar contrast, statins reduced the relative risk of CIAKI by 58% versus NS, and 51% versus placebo. There were no significant differences across all the treatments in terms of risk of hemodialysis or all-cause mortality. Statins had the highest probability for reducing the risk of CIAKI (SUCRA, 0.86), risk of hemodialysis (SUCRA, 0.88) and all-cause mortality (SUCRA, 0.81).
CONCLUSION
Statins were the superior preventive strategy for reducing the risk of CIAKI compared with NS alone and placebo.

Identifiants

pubmed: 30757995
pii: S1553-8389(18)30249-5
doi: 10.1016/j.carrev.2018.06.005
pii:
doi:

Substances chimiques

Contrast Media 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Sodium Bicarbonate 8MDF5V39QO
Acetylcysteine WYQ7N0BPYC

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-37

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Safi U Khan (SU)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA. Electronic address: safinmc@gmail.com.

Muhammad U Khan (MU)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Hammad Rahman (H)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Muhammad Shahzeb Khan (MS)

Cook County Hospital, Chicago, OH, USA.

Haris Riaz (H)

Cleveland Clinic, Cleveland, OH, USA.

Matthew Novak (M)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA.

Isaac Opoku-Asare (I)

Howard University Hospital, Washington, DC, USA.

Edo Kaluski (E)

Guthrie Health System/Robert Packer Hospital, Sayre, PA, USA; Rutgers New Jersey Medical School, Newark, NJ, USA; The Geisinger Commonwealth Medical College, Scranton, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH